Ischemia-reperfusion (IR)-induced
acute lung injury (ALI) is implicated in several clinical conditions like
lung transplantation, acute
pulmonary embolism after
thrombolytic therapy, re-expansion of collapsed lung from
pneumothorax or
pleural effusion,
cardiopulmonary bypass and etc. Because mortality remains high despite advanced medical care, prevention and treatment are important clinical issues for IR-induced ALI.
Vascular endothelial growth factor (
VEGF) has a controversial role in ALI. We therefore conducted this study to determine the effects of anti-
VEGF antibody in IR-induced ALI. In the current study, the IR-induced ALI was conducted in a rat model of isolated-perfused lung in situ in the chest. The animals were divided into the control, control + preconditioning anti-
VEGF antibody (
bevacizumab, 5mg/kg), IR, IR + preconditioning anti-
VEGF antibody (1mg/kg), IR+ preconditioning anti-
VEGF antibody (5mg/kg) and IR+ post-IR anti-
VEGF antibody (5mg/kg) group. There were eight adult male Sprague-Dawley rats in each group. The IR caused significant pulmonary micro-vascular hyper-permeability,
pulmonary edema, neutrophilic infiltration in lung tissues, increased
tumor necrosis factor-α, and total
protein concentrations in bronchoalveolar lavage fluid.
VEGF and
extracellular signal-regulated kinase (ERK) were increased in IR-induced ALI. Administration of preconditioning anti-
VEGF antibody significantly suppressed the
VEGF and ERK expressions and attenuated the IR-induced
lung injury. This study demonstrates the important role of
VEGF in early IR-induced ALI. The beneficial effects of preconditioning anti-
VEGF antibody in IR-induced ALI include the attenuation of
lung injury, pro-inflammatory
cytokines, and neutrophilic infiltration into the lung tissues.